Related Articles
Safety and continuity of second‑ and third‑line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer
Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer
Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: A preliminary study
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer